HomeTrialNCT05829291
🔬NCT05829291NARECRUITING

Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases

Study Summary

This is a single center study enrolling up to 10 patients. The primary objective is to Evaluate the feasibility and safety of the DaRT for the treatment of Liver Metastases. The secondary objective is to evaluate the pathological response of liver metastases according to the Modified tumor regression grade\[1\] and to evaluate the radiological response of liver metastases using the RECIST criteria.

View on ClinicalTrials.gov ↗
Study Details
Enrollment10 participants
Primary Completion
Lead SponsorAlpha Tau Medical LTD.
Data Retrieved2026-06-17 02:56:49.846018+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.